Advertisement

Surgery for Stage IV Melanoma

Chapter
  • 182 Downloads

Abstract

Although metastatic melanoma was historically associated with poor response to systemic therapy, limited surgical options, and an overall grim prognosis, advances over the past decade have resulted in a dramatic shift in the availability and effectiveness of treatments for these patients. In particular, the development of immune checkpoint inhibitors and targeted therapy has offered many melanoma patients with advanced disease a chance for improved survival and even, in some cases, cure. Importantly, these improvements in systemic therapy have created more potential candidates for surgery at more advanced stages, both for palliative and curative intent. However, given the complex considerations for patients with stage IV melanoma, a multi-disciplinary approach and appropriate patient selection for metastasectomy is critical in order to provide these patients with optimal outcomes.

Keywords

Metastatic melanoma Consolidation surgery Palliative surgery Metastasectomy 

Notes

Conflict of Interest

The authors declare that they have no financial conflicts of interest relevant to this work.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Rueth NM, Cromwell KD, Cormier JN. Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am. 2015;24:359–77.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Harada K, Mizrak Kaya D, Shimodaira Y, et al. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol. 2017;13:919–34.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:2105–10.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Ollila DW, Caudle AS. Surgical management of distant metastases. Surg Oncol Clin N Am. 2006;15:385–98.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Tyrell R, Antia C, Stanley S, Deutsch GB. Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma Manag. 2017;4:61–8.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Bhatia S, Thompson JA. Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Compr Cancer Netw. 2012;10:403–12.CrossRefGoogle Scholar
  8. 8.
    Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl 1):S11–4.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117:4740–06.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Markowitz JS, Cosimi LA, Carey RW, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg. 1991;126:703–7; discussion 707–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Gadd MA, Coit DG. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma. Arch Surg. 1992;127:1412–6.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16:1103–11.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983–91.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Karp NS, Boyd A, DePan HJ, et al. Thoracotomy for metastatic malignant melanoma of the lung. Surgery. 1990;107:256–61.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Gorenstein LA, Putnam JB, Natarajan G, et al. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg. 1991;52:204–10.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Harpole DH Jr, Johnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 1992;103:743–8; discussion 748–50.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery. 1994;115:295–302.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Tafra L, Dale PS, Wanek LA, et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110:119–28; discussion 129.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    La Hei E, Thompson J, McCaughan B, et al. Surgical resection of pulmonary metastatic melanoma: a review of 83 thoracotomies. Asia Pacific Heart J. 1996;5:111–4.CrossRefGoogle Scholar
  22. 22.
    Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol. 1998;69:206–11.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Leo F, Cagini L, Rocmans P, et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer. 2000;83:569–72.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Andrews S, Robinson L, Cantor A, DeConti RC. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control. 2006;13:218–23.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133:104–10.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Neuman HB, Patel A, Hanlon C, et al. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14:2847–53.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ricaniadis N, Konstadoulakis MM, Walsh D, Karakousis CP. Gastrointestinal metastases from malignant melanoma. Surg Oncol. 1995;4:105–10.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975–9; 979–80.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Haigh PI, Essner R, Wardlaw JC, et al. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol. 1999;6:633–9.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Agrawal S, Yao TJ, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol. 1999;6:336–44.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Wood TF, DiFronzo LA, Rose DM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol. 2001;8:658–62.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950–5.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Collinson FJ, Lam TK, Bruijn WM, et al. Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. Ann Surg Oncol. 2008;15:1741–9.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10:287–93.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293–300.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Fletcher WS, Pommier RF, Lum S, Wilmarth TJ. Surgical treatment of metastatic melanoma. Am J Surg. 1998;175:413–7.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24:3991–4000.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Faries MB, Leung A, Morton DL, et al. A 20-year experience of hepatic resection for melanoma: is there an expanding role? J Am Coll Surg. 2014;219:62–8.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Deutsch GB, Flaherty DC, Kirchoff DD, et al. Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965–2014: relevance of surgical cure in the era of modern systemic therapy. JAMA Surg. 2017;152:672–8.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Hanna TP, Nguyen P, Baetz T, et al. A population-based study of survival impact of new targeted and immune-based therapies for metastatic or unresectable melanoma. Clin Oncol (R Coll Radiol). 2018;30:609–17.CrossRefGoogle Scholar
  45. 45.
    Smith MJF, Smith HG, Joshi K, et al. The impact of effective systemic therapies on surgery for stage IV melanoma. Eur J Cancer. 2018;103:24–31.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Bello DM, Panageas KS, Hollmann T, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol. 2019.  https://doi.org/10.1245/s10434-019-08099-9. [Epub ahead of print].
  47. 47.
    Aubin JM, Rekman J, Vandenbroucke-Menu F, et al. Systematic review and meta-analysis of liver resection for metastatic melanoma. Br J Surg. 2013;100:1138–47.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Deutsch GB, Kirchoff DD, Faries MB. Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am. 2015;24:279–98.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Lasithiotakis K, Zoras O. Metastasectomy in cutaneous melanoma. Eur J Surg Oncol. 2017;43:572–80.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Reddy S, Han D. Surgical management of distant organ metastases. In: Kluger H, Ariyan S, editors. The melanoma handbook. New York: Elsevier; 2014.Google Scholar
  53. 53.
    Wei IH, Healy MA, Wong SL. Surgical treatment options for stage IV melanoma. Surg Clin North Am. 2014;94:1075–89. ixPubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev. 2008;34:614–20.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245:591–6.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Chua TC, Scolyer RA, Kennedy CW, et al. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol. 2012;19:1774–81.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Hanna TP, Chauvin C, Miao Q, et al. Clinical outcomes after pulmonary metastasectomy for melanoma: a population-based study. Ann Thorac Surg. 2018;106:1675–81.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Guerrini GP, Lo Faso F, Vagliasindi A, et al. The role of minimally invasive surgery in the treatment of lung metastases. J Investig Surg. 2017;30:110–5.CrossRefGoogle Scholar
  59. 59.
    Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712–20.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2011;7:1383–94.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Hughes MS, Zager J, Faries M, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23:1309–19.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Goldinger SM, Panje C, Nathan P. Treatment of melanoma brain metastases. Curr Opin Oncol. 2016;28:159–65.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Ray S, Dacosta-Byfield S, Ganguli A, et al. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neuro-Oncol. 2013;114:117–25.CrossRefGoogle Scholar
  65. 65.
    Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–30.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    McWilliams RR, Brown PD, Buckner JC, et al. Treatment of brain metastases from melanoma. Mayo Clin Proc. 2003;78:1529–36.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Pinkham MB, Sahgal A, Pullar AP, Foote MC. In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely. BMC Cancer. 2017;17:768.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Lonser RR, Song DK, Klapper J, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg. 2011;115:30–6.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117:1697–703.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Sahgal A, Larson D, Knisely J. Stereotactic radiosurgery alone for brain metastases. Lancet Oncol. 2015;16:249–50.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24:135–41.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Mavor ME, Richardson H, Miao Q, et al. Disparities in diagnosis of advanced melanoma: a population-based cohort study. CMAJ Open. 2018;6:E502–12.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2021

Authors and Affiliations

  1. 1.Section of Surgical Oncology, Department of SurgeryYale School of MedicineNew HavenUSA
  2. 2.Division of Surgical Oncology, Department of SurgeryOregon Health & Science UniversityPortlandUSA

Personalised recommendations